Revelation BiosciencesREVB +3.16%28 Pretax Margin % is % as of Mar. 2026. GuruFocus rates REVB with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 946 Biotechnology companies, Revelation Biosciences ranks worse than 105708.14% on this metric.
The historical rank and industry rank for Revelation Biosciences's Pretax Margin % or its related term are showing as below:
REVB's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.5 * Ranked among companies with meaningful Pretax Margin % only.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Revelation Biosciences Pretax Margin % Related Terms
Revelation Biosciences Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Revelation Biosciences's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
REVB vs ITRMF, ENSC, PPCB: Pretax Margin % Comparison
For the Biotechnology subindustry, Revelation Biosciences's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revelation Biosciences Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Revelation Biosciences's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Revelation Biosciences's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revelation Biosciences (REVB) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Revelation Biosciences and its competitors. According to the industry distribution chart, Revelation Biosciences ranks #999999 out of 946 companies in the Biotechnology industry.
Is Revelation Biosciences' Pretax Margin % too high?
Revelation Biosciences' current Pretax Margin % is %. Based on the distribution chart, Revelation Biosciences ranks #999999 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Revelation Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Revelation Biosciences' Pretax Margin % compare to ITRMF and ENSC?
According to the Biotechnology industry distribution chart, Revelation Biosciences ranks #999999 out of 946 companies for Pretax Margin %. This places Revelation Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Revelation Biosciences and its competitors. Revelation Biosciences's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revelation Biosciences stock overvalued right now?
Revelation Biosciences (REVB) has a current Pretax Margin % of %. The current Pretax Margin % is %. Revelation Biosciences' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Revelation Biosciences (REVB), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
28GF Score
Get the complete analysis for REVB
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REVB has been successfully added to your 
